Elias I. Traboulsi

Elias I. Traboulsi

Auto-generated profile, based on publicly available information

Elias I. Traboulsi

Cleveland Clinic Cole Eye Institute, Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in Ophthalmology
Verified
Journal Article
Closed access
SWSaloni Walia
Saloni Walia
GFGerald A. Fishman
Gerald A. Fishman
SJSamuel Jacobson
Samuel Jacobson
TATomas S. Aleman
Tomas S. Aleman
RKRobert Koenekoop
Robert Koenekoop
ESEdwin M. Stone
Edwin M. Stone

21 October 2011 in Ophthalmic Genetics
Verified
Journal Article
Closed access
PDF file
RCRazek Georges Coussa
Razek Georges Coussa
JKJames Kim
James Kim
ETElias I. Traboulsi
Elias I. Traboulsi
Background/aims: The extent and time course of vision loss in Choroideremia (CHM) is still unclear. We undertook this study to quantitate the change in visual acuity (VA) over time in order to gain a better understanding of the natural course of this retinal disorder. Methods: Corrected VA of 120 males with CHM and 53 female carriers were collected from 24 studies and/or case reports published between 1981 and 2010, as well as from data on 15 patients examined at the Cole Eye Institute (Cleveland Clinic). Cross-sectional and longitudinal analyses were used to investigate the relationship between VA and age, as well as the progression rate of VA with age, respectively. Age grouping effects were investigated using ANOVA. Results: The mean age of affected males was 36.6 ± 17.7 years. The mean logMAR VA was 0.35 ± 0.53. There was a significant 0.0072 decrease in logMAR VA per year (p = 1.22 × 10-4). There was a significant difference between VA of patients 50 years (0.27 ± 0.39 vs. 0.61 ± 0.81, p = 2.90 × 10-5). When we compared the rate of VA loss for patients 50 years, we also found a significant difference (0.01 ± 0.04 vs. 0.06 ± 0.08, p = 1.23 × 10-2). The average age of female carriers was 36.4 ± 17.7 years, with an average logMAR VA of 0.36 ± 0.6. There was no significant correlation between VA of female carriers and age (p = 0.12) with 46% of female carriers having a VA better than 20/20 at an average age of 33 years compared to 25% of affected males at 30 years. Conclusion: In affected males with CHM, VA decreases very slowly until subjects reach 50 years of age, at which time the rate and extent of vision loss become significantly higher. Additionally, VA decreases more rapidly as individuals get older. In contradistinction to affected males, VA loss in female carriers is much milder.

18 May 2007 in BMC Genomic Data
Verified
Journal Article
Open access
PDF file
WCWai-Man Chan
Wai-Man Chan
CACaroline Andrews
Caroline Andrews
LDLaryssa Dragan
Laryssa Dragan
DFDouglas Fredrick
Douglas Fredrick
LALinlea Armstrong
Linlea Armstrong
EEElizabeth C Engle
Elizabeth C Engle
Background: Congenital fibrosis of the extraocular muscles types 1 and 3 (CFEOM1/CFEOM3) are autosomal dominant strabismus disorders that appear to result from maldevelopment of ocular nuclei and nerves. We previously reported that most individuals with CFEOM1 and rare individuals with CFEOM3 harbor heterozygous mutations in KIF21A. KIF21A encodes a kinesin motor involved in anterograde axonal transport, and the familial and de novo mutations reported to date predictably alter one of only a few KIF21A amino acids – three within the third coiled-coil region of the stalk and one in the distal motor domain, suggesting they result in altered KIF21A function. To further define the spectrum of KIF21A mutations in CFEOM we have now identified all CFEOM probands newly enrolled in our study and determined if they harbor mutations in KIF21A. Results: Sixteen CFEOM1 and 29 CFEOM3 probands were studied. Three previously unreported de novo KIF21A mutations were identified in three CFEOM1 probands, all located in the same coiled-coil region of the stalk that contains all but one of the previously reported mutations. Eight additional CFEOM1 probands harbored three of the mutations previously reported in KIF21A; seven had one of the two most common mutations, while one harbored the mutation in the distal motor domain. No mutation was detected in 5 CFEOM1 or any CFEOM3 probands. Conclusion: Analysis of sixteen CFEOM1 probands revealed three novel KIF21A mutations and confirmed three reported mutations, bringing the total number of reported KIF21A mutations in CFEOM1 to 11 mutations among 70 mutation positive probands. All three new mutations alter amino acids in heptad repeats within the third coiled-coil region of the KIF21A stalk, further highlighting the importance of alterations in this domain in the etiology of CFEOM1.

11 November 2010 in BMC Genomic Data
Verified
Journal Article
Open access
PDF file
AHAnneke I Den Hollander
Anneke I Den Hollander
JBJanisha Biyanwila
Janisha Biyanwila
PKPeter Kovach
Peter Kovach
TBTanya Bardakjian
Tanya Bardakjian
ETElias I Traboulsi
Elias I Traboulsi
JMJarema Malicki
Jarema Malicki
Background: The size of the vertebrate eye and the retina is likely to be controlled at several stages of embryogenesis by mechanisms that affect cell cycle length as well as cell survival. A mutation in the zebrafish out of sight (out) locus results in a particularly severe reduction of eye size. The goal of this study is to characterize the out m233 mutant, and to determine whether mutations in the out gene cause microphthalmia in humans. Results: In this study, we show that the severe reduction of eye size in the out m233 mutant is caused by a mutation in the zebrafish gdf6a gene. Despite the small eye size, the overall retinal architecture appears largely intact, and immunohistochemical studies confirm that all major cell types are present in out m233 retinae. Subtle cell fate and patterning changes are present predominantly in amacrine interneurons. Acridine orange and TUNEL staining reveal that the levels of apoptosis are abnormally high in out m233 mutant eyes during early neurogenesis. Mutation analysis of the GDF6 gene in 200 patients with microphthalmia revealed amino acid substitutions in four of them. In two patients additional skeletal defects were observed. Conclusions: This study confirms the essential role of GDF6 in the regulation of vertebrate eye size. The reduced eye size in the zebrafish out m233 mutant is likely to be caused by a transient wave of apoptosis at the onset of neurogenesis. Amino acid substitutions in GDF6 were detected in 4 (2%) of 200 patients with microphthalmia. In two patients different skeletal defects were also observed, suggesting pleitrophic effects of GDF6 variants. Parents carrying these variants are asymptomatic, suggesting that GDF6 sequence alterations are likely to contribute to the phenotype, but are not the sole cause of the disease. Variable expressivity and penetrance suggest a complex non-Mendelian inheritance pattern where other genetic factors may influence the outcome of the phenotype.

1 April 2014 in Journal of American Association for Pediatric Ophthalmology and Strabismus
Verified
Journal Article
Closed access
VUVirginia Miraldi Utz
Virginia Miraldi Utz
RCRazek Georges Coussa
Razek Georges Coussa
ETElias I. Traboulsi
Elias I. Traboulsi

1 August 2005 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
SCS H Chavala
S H Chavala
ASA Sari
A Sari
HLH Lewis
H Lewis
GPG J T Pauer
G J T Pauer
ESE Simpson
E Simpson
ETE I Traboulsi
E I Traboulsi